__NUXT_JSONP__("/drugs/Brilanestrant", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.",fdaUniiCode:"9MM2R1A06R",identifier:"C106235",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C2116"],synonyms:["ARN-810","BRILANESTRANT",a,"GDC-0810","RO7056118","SERD ARN-810"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FBrilanestrant",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Brilanestrant","","2021-10-30T13:17:54.303Z")));